Holen Sie sich die Stockscreener-App
1.41
0.00%
0.00
Handel nachbörslich:
1.38
-0.03
-2.13%
Schlusskurs vom Vortag:
$1.41
Offen:
$1.44
24-Stunden-Volumen:
371.56K
Relative Volume:
0.77
Marktkapitalisierung:
$79.76M
Einnahmen:
$3.67M
Nettoeinkommen (Verlust:
$-13.83M
KGV:
-5.0357
EPS:
-0.28
Netto-Cashflow:
$-10.79M
1W Leistung:
+3.68%
1M Leistung:
+13.71%
6M Leistung:
+96.54%
1J Leistung:
+6.82%
1-Tages-Spanne:
$1.32
$1.4799
1-Wochen-Bereich:
$1.32
$1.66
52-Wochen-Spanne:
$0.48
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
Firmenname
Icecure Medical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ICCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.41 | 79.76M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Icecure Medical Ltd Aktie (ICCM) Neueste Nachrichten
IceCure Medical Ltd. Submits Filing for Regulatory Approval of Its Next-Generation XSense? Cryoablation System in Israel - Marketscreener.com
IceCure seeks Israel approval for XSense cryoablation system By Investing.com - Investing.com South Africa
Can IceCure's New Cryoablation System Capture the $174B Minimally Invasive Surgery Market? - StockTitan
A stock that deserves closer examination: Icecure Medical Ltd (ICCM) - US Post News
IceCure Medical Ltd (NASDAQ:ICCM) Sees Significant Drop in Short Interest - Defense World
Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Decreases By 9.2% - MarketBeat
IceCure Medical Ltd's (NASDAQ:ICCM) Profit Outlook - Yahoo Finance
IceCure gets favorable FDA AdCom vote for ProSense System - MSN
IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates - StreetInsider.com
IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision - PR Newswire
IceCure Medical (NASDAQ:ICCM) Shares Down 1.6%Here's What Happened - MarketBeat
ICCMIceCure Medical Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod - MSN
IceCure submits application to China’s NMPA for cryoablation system approval - Yahoo! Voices
IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China - The Malaysian Reserve
IceCure Medical (NASDAQ:ICCM) Stock Price Down 1.6% – Should You Sell? - Defense World
IceCure Medical Ltd. Files for Regulatory Approval of ProSense Cryoablation System in China - Marketscreener.com
Icecure Medical Announces Equity Distribution Agreement - TipRanks
IceCure Medical Reports Strong Growth and Anticipates FDA Approval in 2025 - TipRanks
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America - Longview News-Journal
IceCure Medical Reports 42% North American Growth as ProSense Cancer Treatment Shows 96% Success Rate - StockTitan
Investors bid IceCure Medical (NASDAQ:ICCM) up US$14m despite increasing losses YoY, taking five-year CAGR to 43% - Simply Wall St
The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing - Yahoo Finance
Financial Analysis: SANUWAVE Health (OTCMKTS:SNWV) versus IceCure Medical (NASDAQ:ICCM) - Defense World
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule - Kilgore News Herald
IceCure Medical regains full Nasdaq compliance - Medical Buyer
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minim - GuruFocus.com
IceCure Medical Regains Nasdaq Compliance, Securing Market Position - TipRanks
IceCure to Meet Institutional Investors at the H.C. Wainwright a - GuruFocus.com
IceCure Medical regains Nasdaq compliance - Investing.com
IceCure earns European patent win for next-gen cryoablation tech - Mass Device
IceCure Medical Ltd. Receives an Intention to Grant Notice from the European Patent Office - Marketscreener.com
Icecure Nicks Up On European OK For Connector - MENAFN.COM
IceCure Nicks Up on European OK for Connector - Baystreet.ca
European Patent Office Issues Intention to Grant Notice to IceCu - GuruFocus.com
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology - Marketscreener.com
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference - GuruFocus.com
IceCure Medical appoints new board director - Investing.com India
IceCure Medical appoints new board director By Investing.com - Investing.com Australia
Icecure Medical Appoints New Board Director with Financial Expertise - TipRanks
IceCure Medical Ltd Appoints Li Haixiang as Director - Marketscreener.com
IceCure Medical (NASDAQ:ICCM) Stock Price Down 0.4%Here's Why - MarketBeat
IceCure Medical (NASDAQ:ICCM) Shares Down 0.4% – What’s Next? - Defense World
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting - Marketscreener.com
IceCure Medical's ProSense Shows Breakthrough 5-Year Breast Cancer Treatment Results in Major Clinical Trial - StockTitan
Study Published in the British Journal of Radiology Demonstrates - GuruFocus.com
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - The Eastern Progress Online
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - The Eastern Progress Online
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - Kilgore News Herald
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery - The Eastern Progress Online
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - The Eastern Progress Online
Finanzdaten der Icecure Medical Ltd-Aktie (ICCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):